Achieve Life Sciences is a late-stage clinical specialty pharmaceutical company focused on the development and commercialization of cytisinicline, a treatment for nicotine dependence. The company's primary product candidate, cytisinicline, is a naturally occurring alkaloid that acts as a partial agonist and antagonist on nicotinic acetylcholine receptors to reduce cravings and withdrawal symptoms associated with smoking and e-cigarette use. Achieve holds an exclusive license and supply agreement with Sopharma AD for the development and commercialization of cytisinicline outside of Sopharma’s territories, which include Central and Eastern Europe, Scandinavia, North Africa, the Middle East, Central Asia, and Vietnam. The company is developing cytisinicline for two main indications: smoking cessation and nicotine e-cigarette cessation. In September 2025, the FDA accepted a New Drug Application for cytisinicline for smoking cessation, with a targeted action date of June 2026. The company has partnered with Adare Pharma Solutions for U.S.-based manufacturing to support commercial launch, which is anticipated to occur in the first half of 2027. Achieve targets markets in the United States, the European Union, and other regions outside of Sopharma’s licensed territories.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - Specialty & Generic Homepage achievelifesciences.com
Sector Healthcare IR page ir.achievelifesciences.com
Tags
nicotine dependence, smoking cessation, e-cigarette cessation, specialty pharmaceuticals, clinical stage, nicotinic acetylcholine receptors, alkaloid therapy, cytisinicline, cytisine, Sopharma AD, Adare Pharma Solutions
Press page ir.achievelifesciences.com/news-events/press-releases

Metrics

Valuation  
Market cap $ 932.336M
Market cap (USD) $ 932.336M
P/E -6.39
PEG —
P/BV 5.16
P/S 36.51
P/OCF -21.17
P/FCF -18.85
Dividend yield —
Turnover / mcap —
Returns  
ROE -257.7%
ROI -150.1%
ROIC -113.1%
Profit margin —
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) —
Debt/Equity 69.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 43
Quality score -50.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2007 FY 2006 FY 2005 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999 FY 1998
Revenue 20.131M — 8.254M — — 8.749M — 12.05M 5.1M
Net profit -13.063M -23.551M -21.097M -10.467M -11.636M 542.177K -2.147M 434.67K -11.173M
Free cash flow — — -8.479M -10.596M -11.305M 1.061M — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 478,000 9,000 7,000 8,000 — — — — — —
↳ YoY growth +3,314.3% -98.1% -22.2% +14.3%
↳ 5y CAGR -10.1% -58.3% -75.9% -73.1%
Lease liabilities (USD) — — 23,000 362,000 169,000 73,000 127,000 69,000 121,000 66,000
Cash and deposits (USD) 15.2M 5.28M 9.52M 16.7M 35.9M 43M 24.8M 15.5M 12.8M 20.9M
Intangible assets (USD) 2.76M 2.53M 2.31M 2.09M 1.86M 1.64M 1.42M 1.2M 974,000 751,000
Right-of-use assets (USD) — — — 329,000 146,000 64,000 123,000 66,000 119,000 64,000
Cash flow detail
Operating cash flow (USD) -29.7M -9.11M -10.6M -15.2M -13.5M -29.4M -37.5M -24.5M -29.8M -49.5M
Purchases of property, plant and equipment (USD) -46,000 — -46,000 -53,000 -17,000 — — -21,000 — -3,000
Change in receivables (cash effect) (USD) -464,000 -9,000 2,000 -1,000 — — — — — —
Income taxes paid (cash effect) (USD) — — — — — — — 0.00 0.00 0.00
Share-based compensation (USD) 1.65M 348,000 854,000 1.2M 1.29M 2.19M 3.27M 3.44M 5.33M 8.76M
Operating cash flow before change in receivables (USD) -29.2M -9.1M -10.6M -15.2M — — — — — —
Free cash flow (OCF - PPE - intangibles) (USD) -29.7M — -10.7M -15.3M -13.5M — — -24.5M — -49.5M
Income detail
Research and development expense (USD) 14.8M 3.1M 5.87M 9.67M 6.88M 24M 30.1M 15.8M 22.8M —
↳ 5y CAGR -7.3% -40.0% -36.2% -26.9% -22.8% +10.1% +57.5% +21.9% +18.7%
Total comprehensive income (USD) -20.1M -10.6M -12.7M -16.4M — — -42.4M -29.8M -39.8M -54.7M
Comprehensive income to owners (USD) -20.1M -10.6M -12.7M -16.4M — — -42.4M -29.8M -39.8M -54.7M
Reported Nov 9, 2017 Mar 1, 2018 May 15, 2019 Mar 13, 2020 Mar 11, 2021 Mar 10, 2022 Mar 11, 2025 Mar 24, 2026 Mar 24, 2026 Mar 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Presented 52-week ORCA-OL data at the CHEST 2026 Annual Meeting showing that nearly one in three adults still smoking or vaping after a supervised quit attempt in a prior trial (a median of five quit attempts among those who smoked) had quit by the end of treatment, with quit rates rising over the course of the year

Expanded leadership team with two senior appointments, strengthening the launch team

Completed three commercial-scale stability batches for U.S.-based finished drug product manufacturing; NDA resubmission remains on track for the fourth quarter of 2026

Cash, cash equivalents, and marketable securities of $201.5 million as of September 30, 2026

SEATTLE and VANCOUVER, British Columbia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc., doing business as AchieveRx (AchieveRx or the Company) (Nasdaq: QUIT), a late-stage pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced financial results for the third quarter of 2026 and provided business updates.

November 02, 2026 8:30am EST Download as PDF

SEATTLE and VANCOUVER, British Columbia, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that the Compensation Committee of Achieve’s Board of Directors approved stock option grants to purchase an aggregate of 97,000 shares of its common stock and restricted stock unit (“RSU”) awards covering an aggregate of 97,000 shares of its common stock for three new employees.

The stock options have an exercise price equal to the closing price of Achieve’s common stock on the applicable grant date. Each stock option has a four-year vesting period and will vest as to 25% of the shares underlying the stock option on the first anniversary following commencement of employment. The remaining 75% of the shares underlying the stock option will vest in 36 equal monthly installments thereafter, subject to the employee’s continued service through each applicable vesting date.

Each RSU award represents the right to receive one share of Achieve’s common stock upon vesting, subject to the recipient’s continued service. The RSUs will vest over four years with 25% of the underlying shares vesting on each anniversary following commencement of employment, subject to the employee’s continued service through each applicable vesting date.

The stock options and RSU awards are subject to the terms and conditions of the 2024 Equity Inducement Plan, as well as the terms and conditions of the stock option agreement or RSU award agreement covering the grants and were made as an inducement material to the individuals entering into employment with Achieve in accordance with Nasdaq Listing Rule 5635(c)(4).

About Cytisinicline
There are approximately 25 million adults in the United States who smoke combustible cigarettes.¹ Cytisinicline is an investigational compound that binds to nicotinic receptors. It is being developed as an aid to smoking cessation treatment in adults and as an aid to nicotine e-cigarette cessation.

About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence. Achieve’s New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two successfully completed Phase 3 studies and an open-label long-term safety study. Achieve has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements Achieve makes regarding the timing, nature and outcome of cytisinicline clinical development and regulatory review and approval, data results, the timing, nature and success of Achieve’s commercialization activities, the potential market size for cytisinicline, the potential benefits, efficacy, safety and tolerability of cytisinicline, the development and effectiveness of new treatments, the performance of Achieve’s third-party manufacturing partners, the successful launch and commercialization of cytisinicline, and statements concerning Achieve Life Sciences’ future plans and prospects. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including those described in Achieve’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Achieve Contact
Nicole Jones
VP, Strategic Communications and Stakeholder Relations
[email protected]

[email protected]

425-686-1510

Reference
¹Agaku I. Tobacco Product Use among U.S. Adults, 2023–2024, NEJM Evidence, doi: 10.1056/EVIDpha2500339.

Primary Logo

Source: Achieve Life Sciences

Released November 2, 2026

About

For Investors

Recent News

Nov 2, 2026
Achieve Life Sciences Announces Granting of New Hire Inducement Awards

More News

© Copyright 2026 | Achieve Life Sciences, Inc., Inc. All Rights Reserved

IR Calendar Bull 0 Bear 0 Routine

Investors

Investors

Upcoming Events

There are no upcoming events scheduled at this time. Sign up here to receive notices about upcoming events and press releases.

Past Events

Oct 20, 2026 2:09 pm MST – 2:13 pm MST

CHEST 2026

Jul 2, 2026 9:00 am PST

Annual Meeting of Stockholders

May 12, 2026 8:30 am EST

First Quarter 2026 Earnings Conference Call

View All Past Events

About

For Investors

Recent News

Nov 2, 2026
Achieve Life Sciences Announces Granting of New Hire Inducement Awards

More News

© Copyright 2026 | Achieve Life Sciences, Inc., Inc. All Rights Reserved

Prompts

Achieve Life Sciences, Inc. (ticker ACHV), listed in United States.

Company History

Date Change Detail
Apr 24, 2017 Renamed ONCOGENEX PHARMACEUTICALS, INC. → ACHIEVE LIFE SCIENCES, INC.
Aug 21, 2008 Renamed SONUS PHARMACEUTICALS INC → ONCOGENEX PHARMACEUTICALS, INC.

ETFs Holding Achieve Life Sciences, Inc.

ETF Weight in ETF Shares Market value As of
SURI 8.37% 932,105 $ 5.704M Nov 17, 2026
VFMO 0.07% 166,294 $ 1.32M Aug 31, 2026
FSEG 0.02% 165 $ 1,077.45 Jun 30, 2026
RESM 0.02% 93 $ 607.29 Jun 30, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
ACHV Common share — US nasdaq 8.09 USD 2026-09-30
QUIT canonical Common share — US nasdaq — —